Natural anticoagulants and the liver
The regulation of blood coagulation is dependent on a complex interplay between procoagulant, anticoagulant and fibrinolytic proteins. Most of these proteins are synthesised in the liver and their levels are altered in patients with liver disease. The liver also plays an important role in the regulation of haemostasis throughout the clearance of activated clotting factors. It is therefore not surprising that the critically balanced coagulation system is dysregulated in patients with liver disease. In moderate liver failure bleeding disorders predominate, whereas in more advanced liver disease intravascular coagulation is commonly observed and contributes to the overall dysregulation of blood coagulation. In some patients, liver disease can be primarily caused by an abnormality of the coagulation system. These patients usually have a hypercoagulable state caused by a deficiency of a component of the natural anticoagulant system. These include protein C, protein S and antithrombin III. More recently, activated protein C resistance caused by a point mutation in the Factor V gene has been identified as an important risk factor for thrombosis. In these patients the abnormal Factor V is resistant to cleavage by activated protein C re...Continue Reading
A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S
Identification of two distinct heparin cofactors in human plasma. Separation and partial purification
Identification of two distinct heparin cofactors in human plasma. II. Inhibition of thrombin and activated factor X
Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis
Haemostasis unbalance in Pugh-scored liver cirrhosis: characteristic changes of plasma levels of protein C versus protein S
Blood loss, predictors of bleeding, transfusion practice and strategies of blood cell salvaging during liver transplantation
Effect of antithrombin, protein C and protein S on portal vein thrombosis in liver cirrhosis: a meta-analysis
Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease
Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma
Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome: a systematic review and meta-analysis of observational studies
Erythrocytic phosphatidylserine exposure and hemostatic alterations in β-thalassemia intermediate patients
Review article: the aetiology of primary Budd-Chiari syndrome - differences between the West and China
Activation of human coagulation system by liver-derived clotting factors of Banna minipig inbred line
Thromboelastography used to assess coagulation during treatment with molecular adsorbent recirculating system
Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism
Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management
Comparison of hepatic coagulant, fibrinolytic, and anticoagulant functions between Banna Minipig Inbred line and humans
Universal fresh-frozen plasma (Uniplas): an exploratory study in adult patients undergoing elective liver resection
Haemostatic abnormalities in liver disease: could some haemostatic tests be useful as liver function tests?
Thermal treatment stimulus on erythrocyte compatibility and hemostatic behavior of one-dimensional bioactive nanostructures.
Effects of laparoscopic splenectomy and azygoportal disconnection on liver synthesis function and cirrhosis: a 2-year prospective study.
Discovery of a Potential Plasma Protein Biomarker Panel for Acute-on-Chronic Liver Failure Induced by Hepatitis B Virus
Blood Clotting Disorders
Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.
ApoE, Lipids & Cholesterol
Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.